BR112017002325A2 - produto farmacêutico adequado para administração oral, e composição farmacêutica - Google Patents

produto farmacêutico adequado para administração oral, e composição farmacêutica

Info

Publication number
BR112017002325A2
BR112017002325A2 BR112017002325-3A BR112017002325A BR112017002325A2 BR 112017002325 A2 BR112017002325 A2 BR 112017002325A2 BR 112017002325 A BR112017002325 A BR 112017002325A BR 112017002325 A2 BR112017002325 A2 BR 112017002325A2
Authority
BR
Brazil
Prior art keywords
food
oral administration
esophagus
pharmaceutical
product suitable
Prior art date
Application number
BR112017002325-3A
Other languages
English (en)
Inventor
Benhamou Pierre-Henri
Dupont Christophe
Stefan, (Johan) Koppelman
Martin Laurent
Brochard Hervé
Foucher Estelle
Original Assignee
Dbv Technologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dbv Technologies filed Critical Dbv Technologies
Publication of BR112017002325A2 publication Critical patent/BR112017002325A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a invenção se refere a novas composições e métodos para diagnóstico ou tratamento de alergias alimentares. particularmente, a invenção divulga novas abordagens para a administração de alérgenos alimentares a pacientes alérgicos, por administração oral de formulações que se dissolvem e liberam proteínas no estômago. a invenção permite o tratamento de alergias alimentares através da administração de alérgenos alimentares ao sistema imune intestinal com exposição controlada do esôfago ou da cavidade oral. a invenção também permite realizar desafios alimentares para avaliar o limiar de reatividade clínica, sem expor o esôfago e cavidade oral. a invenção pode ser usada em qualquer indivíduo, particularmente indivíduos humanos, e é aplicável a qualquer alérgeno alimentar.
BR112017002325-3A 2014-08-04 2015-08-03 produto farmacêutico adequado para administração oral, e composição farmacêutica BR112017002325A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14179711.8 2014-08-04
EP14179711 2014-08-04
PCT/EP2015/067853 WO2016020336A1 (en) 2014-08-04 2015-08-03 Compositions of food allergens

Publications (1)

Publication Number Publication Date
BR112017002325A2 true BR112017002325A2 (pt) 2018-01-16

Family

ID=51266147

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017002325-3A BR112017002325A2 (pt) 2014-08-04 2015-08-03 produto farmacêutico adequado para administração oral, e composição farmacêutica

Country Status (11)

Country Link
US (2) US10300133B2 (pt)
EP (1) EP3177318A1 (pt)
JP (1) JP6665159B2 (pt)
KR (1) KR102492411B1 (pt)
CN (1) CN107073104A (pt)
AU (1) AU2015299105B2 (pt)
BR (1) BR112017002325A2 (pt)
CA (1) CA2956881A1 (pt)
IL (1) IL250364B (pt)
MX (1) MX2017001682A (pt)
WO (1) WO2016020336A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
MX2019005925A (es) * 2016-11-21 2019-11-12 Before Brands Inc Composiciones de alergenos liquidas y metodos para la preparacion de las mismas.
AU2016431600B2 (en) 2016-12-05 2024-05-23 Reacta Biotech Limited Oral food challenge meal formulations
SG11202000419QA (en) 2017-07-18 2020-02-27 Before Brands Inc Methods for making mixed allergen compositions
WO2019076477A1 (en) * 2017-10-18 2019-04-25 Luxembourg Institute Of Health (Lih) INDUCTION OF ALLERGEN-SPECIFIC TREGS PRIOR TO ORAL OR SUBLINGUAL IMMUNOTHERAPY OF FOOD ALLERGY
GB201718342D0 (en) * 2017-11-06 2017-12-20 Cambridge Allergy Ltd Allergenic protein formulations for immunotherapy
EP3914098A1 (en) 2019-01-23 2021-12-01 Before Brands, Inc. Methods for making mixed allergen compositions
WO2023198674A1 (en) 2022-04-11 2023-10-19 Alk-Abelló A/S Peanut allergen composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3829589A (en) * 1972-10-24 1974-08-13 A Matsunaga Method of making peanut flour
US4786508A (en) * 1986-05-30 1988-11-22 Warner-Lambert Company Coated dosage forms
NL9300160A (nl) * 1993-01-27 1994-08-16 Sara Lee De Nv Werkwijze voor het bereiden van beklede, geëxpandeerde snackprodukten.
NZ334914A (en) * 1996-10-01 2000-09-29 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture using a phase seperation-coacervation technique
HUP0004625A1 (hu) * 1997-06-11 2001-06-28 The Procter & Gamble Co. Az emésztőcsatorna felső szakaszának fokozott biztonságot nyújtó filmbevonatos tabletta
US20050063994A1 (en) * 2000-04-06 2005-03-24 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
AU2005334837B2 (en) * 2005-07-29 2012-07-19 Stichting Groningen Centre For Drug Research PH-controlled pulsatile delivery system, methods for preparation and use thereof
WO2007112747A1 (en) * 2006-03-31 2007-10-11 Curalogic A/S Immunogen combinations
WO2007112750A2 (en) * 2006-03-31 2007-10-11 Curalogic A/S Tablets and capsules comprising immunogens for oral administration
CN103120653B (zh) * 2007-04-04 2015-09-30 希格默伊德药业有限公司 一种口服药物组合物
NL1036917C2 (nl) * 2009-04-29 2010-11-01 Gijs Weenink Werkwijze voor het vervaardigen van een snack produkt bestaande uit een noot of dergelijke, voorzien van een coating.
JP5911799B2 (ja) * 2009-08-12 2016-04-27 シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ポリマーマトリックスおよび油相を含んで成る免疫調節組成物
WO2012045089A2 (en) * 2010-10-01 2012-04-05 Ventirx Pharmaceuticals, Inc. Methods for the treatment of allergic diseases
WO2013173697A1 (en) * 2012-05-17 2013-11-21 The Johns Hopkins University Orally dissolving thin films containing allergens and methods of making and use

Also Published As

Publication number Publication date
US10300133B2 (en) 2019-05-28
KR20170086016A (ko) 2017-07-25
WO2016020336A1 (en) 2016-02-11
US20170151325A1 (en) 2017-06-01
AU2015299105A1 (en) 2017-03-09
JP2017526663A (ja) 2017-09-14
CA2956881A1 (en) 2016-02-11
IL250364B (en) 2021-12-01
EP3177318A1 (en) 2017-06-14
US10881728B2 (en) 2021-01-05
MX2017001682A (es) 2017-04-27
JP6665159B2 (ja) 2020-03-13
US20190231868A1 (en) 2019-08-01
KR102492411B1 (ko) 2023-01-26
AU2015299105B2 (en) 2020-10-29
IL250364A0 (en) 2017-03-30
CN107073104A (zh) 2017-08-18

Similar Documents

Publication Publication Date Title
BR112017002325A2 (pt) produto farmacêutico adequado para administração oral, e composição farmacêutica
BR112017024777A2 (pt) uso de uma composiçao farmacêutica e de um antibiótico não absorvível para tratamento de transtorno do espectro autista referência cruzada a pedidos relacionados?
NZ745678A (en) Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
EA201791702A1 (ru) Терапевтические средства на основе гликанов и связанные с ними способы
BR112017006957A2 (pt) formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína
WO2018144093A3 (en) ENHANCED SKIN CARE FORMULATIONS
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
PH12014502058A1 (en) Pharmaceutical composition comprising empagliflozin and antiobesity drug
BR112019003410A2 (pt) composições e métodos para modulação da microflora gastrointestinal em um canino
AR106644A1 (es) Composiciones nutricionales sinergísticas y usos de las mismas
BR112015018827A2 (pt) composição farmacêutica oral para tratamento de mucosite oral e estomatite
BR112018000242A2 (pt) composições nutricionais contendo fosfatidiletanolamina, esfingomielina e ácido doco-saexaenóico
BRPI0821895A2 (pt) Composiçao farmacêutica, método de tratamento ou prevenção de uma doença, uma condição e sintomas das mesmas em animais de sangue quente, incluindo seres humanos, método de preparação da composição farmacêutica e método para diagnosticar uma doença, condição, síndrome.
BR102013003570A8 (pt) Composições de plasma rico em plaquetas
BR112021021637A2 (pt) Vacina de subunidade para tratamento ou prevenção de uma infecção do trato respiratório
BR112018008040A2 (pt) composição nutricional compreendendo um hidrolisado de caseína, bem como um butirato dietético e/ou um composto para estimular a formação de butirato endógeno
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual
BR112017018272A2 (pt) métodos de tratamento de diarréia e promoção de saúde intestinal em animais não humanos
EP3424512A4 (en) USES OF ALGINIC ACID SULPHATE IN THE PREPARATION OF MEDICAMENTS AND HEALTH CARE PRODUCTS FOR PREVENTING AND TREATING DISEASES CAUSED BY HUMAN PAPILLOMAVIRUSES
BR112019001423A2 (pt) formulação farmacêutica contendo esomeprazol ou sal farmaceuticamente aceitável e método de preparação
BR112017007364A2 (pt) composição farmacêutica para o uso no tratamento ou prevenção de deficiências de vitaminas e minerais em pacientes que foram submetidos à cirurgia de bypass gástrico
CL2018001589A1 (es) Método para la destoxificación de proteínas del gluten provenientes de granos de cereal y usos de las mismas en el campo médico.
BR112016029619A2 (pt) novas fluoroquinolonas e sesu usos no tratamento de infecções bacterianas
BR112016029749A2 (pt) composições que compreendem cinamaldeído e zinco e métodos de uso de tais composições
BR112016017765A8 (pt) composição compreendendo cinamaldeído e zinco, seu uso, e método para produzir um produto alimentício para perda de peso

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Ipc: A61K 39/35 (2006.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]